Can-Fite BioPharma Ltd. (NYSE: CANF) is an Israeli biopharmaceutical company with pharmaceutical discovery and clinical development stage capabilities, developing treatments for cancer, inflammatory disease, and sexual dysfunction. The company’s CF101 drug candidate is currently under advanced clinical development, preparing to enter phase III trials for rheumatoid arthritis and psoriasis. Can-Fite’s liver cancer drug CF102 is in phase II trials for patients with advanced liver cancer. For more information, visit the company’s website at www.can-fite.com.